320P - Adjuvant chemotherapy comprising a paclitaxel and carboplatin regimen or paclitaxel and ifosfamide regimen for uterine carcinosarcoma, a single ins...

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anti-Cancer Agents & Biologic Therapy
Endometrial Cancer
Presenter Yohei Ohtake
Citation Annals of Oncology (2016) 27 (suppl_9): ix94-ix103. 10.1093/annonc/mdw585
Authors Y. Ohtake1, T. Nishikawa1, H. Yoshida2, M. Ishikawa3, S. Ikeda3, T. Kato3, A. Shimomura1, T. Shimoi1, E. Noguchi1, K. Yonemori1, C. Shimizu1, M. Yunokawa1, K. Tamura1
  • 1Department Of Breast And Medical Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2Department Of Pathology And Clinical Laboratories, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 3Department Of Gynecology, National Cancer Center Hospital, 104-0045 - Tokyo/JP

Abstract

Background

Uterine carcinosarcoma (UCS) is a rare form of cancer with poor prognosis. It is unclear whether adjuvant chemotherapy improves the prognosis in these patients. The aim of this retrospective study was to assess the efficacy of adjuvant chemotherapy after primary surgery for UCS.

Methods

Data for patients who underwent comlete surgical resection of UCS between 2002 and 2015 were retrospectively analyzed. The patients were classified into three groups: those who did not receive adjuvant chemotherapy (the surgery only group), those who received paclitaxel and carboplatin (TC; carboplatin AUC6 + paclitaxel 175mg/m2 q3w, 6 cycles; TC group), and those who received paclitaxel and ifosfamide (TI; ifosfamide 1.6g/m2 + paclitaxel 175mg/m2 q3w, 8 cycles; TI group).We compared the recurrence-free survival (RFS) and overall survival (OS) among the three groups.

Results

A total of 41 patients were identified, with 20 patients in the surgery only group, 7 patients in the TC group, and 14 patients in the IT group. The patient and tumor characteristics in the surgery only group, TC group, and TI group were as follows, respectively: (mean age) 63.5; 56.0; 62.0, (clinical stage I/II/II/IV) 10/0/8/2; 1/1/3/2; 11/1/6/2, (homologous/heterologous with sarcoma component) 11/9; 5/2; 11/3, and (endometrioid/serous/not determined in carcinoma component:) 11/2/7; 1/4/2; 6/7/1. No significant differences in these characteristics were observed between the three groups. Moreover, TC or TI group did not demonstrate significant defferrence in RFS (P = 0.558, 0.410) and OS (P = 0.844, 0.663) compared with the surgery only group.

Conclusions

According to the findings of this study, adjuvant chemotherapy did not improve the RFS and OS in patients with UCS after complete surgical resection. However, the retrospective nature of the study and a small sample size warrant further studies for a definitive conclusion.

Clinical trial indentification

Legal entity responsible for the study

Yohei Ohtake

Funding

Japan Agency for MedicalResearch and Development

Disclosure

All authors have declared no conflicts of interest.